Furthermore, the impact of the tumor microenvironment is likely an important factor in CAR T cell therapy, for example the presence of inhibitory factors such as programmed-death ligand 1 (PD-L1) expression, and work is ongoing to evaluate combining immune checkpoint inhibitors with CAR T cells therapy. The gene discussed is CD274; the disease is neoplasm.